Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Inks Japanese Partnership with Sumitomo Subsidiary

NEW YORK (GenomeWeb News) – MDxHealth today said that it has signed a partnership with a subsidiary of Sumitomo to bring the firm's molecular diagnostics products to the Japanese market.

Liege, Belgium-based MDxHealth said that Sumitomo subsidiary Summit Pharmaceuticals International will market its pharmaco molecular diagnostic epigenetic technologies and products. Specifically, Summit will aim to provide companion diagnostics to pharmaceutical firms in the Japanese market.

"As the global life sciences industry continues to pair diagnostics with therapeutics to determine patient response, we believe this partnership with SPI will provide MDxHealth with the necessary leverage and expertise to penetrate the Japanese market," MDxHealth CEO Jan Groen said in a statement.

Financial and other terms of the alliance were not disclosed.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.